STOCKHOLM – March 29, 2017 – ContextVision, a medical technology company specializing in image analysis and artificial intelligence, has started a collaboration and signed an agreement with ALABplus, one of Poland’s largest provider of pathology services, to secure access to a significant amount of data for deep learning product development within digital pathology.
“The present contract is extremely valuable for ContextVision as we secure access to as much material as we need, which will boost the product development phase”, said Anita Tollstadius, CEO.
In 2015, ContextVision made the strategic decision to enter a new, rapidly growing market, digital pathology, in order to open up for a significant company growth. The company decided to become a major supplier of image analysis products and is heading a three-year Eurostar sponsored research program. In this project, the company is using the powerful deep learning technology for the development of new algorithms.
“The deep learning technology is dependent on the supply of large amounts of data to create well-trained and accurate decision support tools”, said Tollstadius.
The research project initially focused on prostate cancer, but has expanded to include breast cancer and will extend into other cancers. ALABplus handles more than 200,000 patients referrals per year. The center can therefore provide high quality samples from many cancer forms, as well as clinical expertise and valuable data.
“Access to accurate data is a key limiting factor for research progress, and our contract with ALABplus in Warsaw certainly opens up the opportunity to expand our research program”, Tollstadius said.
ContextVision has developed an expertise within deep learning, the latest technology within artificial intelligence, and uses the technology for the creation of new innovative products with the potential to improve healthcare. The company recently placed second in a prestigious competition regarding the analysis of digital pathology images from breast cancer patients.
For further information, please contact ContextVision’s CEO, Anita Tollstadius, at +46 70 337 30 26.
ContextVision is a medical technology company specializing in image analysis and artificial intelligence. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment. As an industry pioneer for more than 30 years, ContextVision is taking a leading position within deep learning, the latest artificial intelligence technology. ContextVision is currently investing significantly in the field to expand its product portfolio. The present product portfolio includes state-of-the-art image enhancement software for 2D/3D/4D ultrasound, MRI, X-ray and mammography which is used by leading equipment manufacturers worldwide. ContextVision is based in Sweden and listed on the Oslo Stock Exchange under the ticker COV. For more information, please visit www.contextvision.com.
ALABplus offers advanced pathologic diagnosis, which includes a wide range of cytology and histopathology services.
ALAB services are carried out by a team of experienced laboratory technicians and specialist pathologists with experience from leading academic and oncology centers in Poland and abroad.